Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Medical Device

Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices

Fineline Cube Mar 19, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Deals

Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution

Fineline Cube Mar 19, 2024

Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with...

Company Deals

C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV

Fineline Cube Mar 19, 2024

Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into...

Company Drug

GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study

Fineline Cube Mar 19, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...

Company

Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs

Fineline Cube Mar 19, 2024

Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue...

Company Deals

uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors

Fineline Cube Mar 18, 2024

uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...

Company Deals Drug

Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia

Fineline Cube Mar 18, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...

Company Drug

BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma

Fineline Cube Mar 18, 2024

BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...

Company Deals

Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080

Fineline Cube Mar 18, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Policy / Regulatory

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Drug

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Fineline Cube Mar 18, 2024

Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...

Company Deals

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Fineline Cube Mar 18, 2024

Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...

Company Deals

CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development

Fineline Cube Mar 18, 2024

CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...

Company Drug

Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer

Fineline Cube Mar 18, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...

Company Drug

Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment

Fineline Cube Mar 18, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...

Company Drug

Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH

Fineline Cube Mar 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study

Fineline Cube Mar 18, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company

Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth

Fineline Cube Mar 18, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...

Company Drug

Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market

Fineline Cube Mar 18, 2024

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...

Posts pagination

1 … 412 413 414 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.